Capmatinib Dosage
Medically reviewed by Drugs.com. Last updated on Sep 6, 2024.
Applies to the following strengths: 150 mg; 200 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Non-Small Cell Lung Cancer
400 mg orally 2 times daily
Use: For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an approved test
Renal Dose Adjustments
Mild (CrCl 60 to 89 mL/min) to moderate (CrCl 30 to 59 mL/min): No adjustment recommended.
Severe (CrCl 15 to 29 mL/min): Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
DOSE MODIFICATION RECOMMENDATIONS:
- First dose reduction: 300 mg orally 2 times daily
- Second dose reduction: 300 mg orally 2 times daily
- Permanently discontinue this drug in patients who are unable to tolerate 200 mg orally 2 times daily.
DOSE MODIFICATION FOR ADVERSE REACTIONS:
INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS:
- Any Grade: Permanently discontinue this drug.
- Grade 3: Withhold therapy until recovery to baseline ALT/AST; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
- Grade 4: Permanently discontinue this drug.
ALT and/or AST greater than 3 times the upper limit of normal (ULN) with total bilirubin greater than 2 x ULN: Permanently discontinue this drug.
INCREASED TOTAL BILIRUBIN WITHOUT CONCURRENT INCREASED ALT AND/OR AST:
- Grade 2: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at the same dose; otherwise resume at a reduced dose.
- Grade 3: Withhold therapy until recovery to baseline bilirubin; if recovered to baseline within 7 days, resume this drug at reduced dose; otherwise permanently discontinue this drug.
- Grade 4: Permanently discontinue this drug.
- Grade 2: Maintain dose level; if intolerable, consider withholding this drug until resolved, then resume at a reduced dose.
- Grade 3: Withhold this drug until resolved then resume at reduced dose.
- Grade 4: Permanently discontinue this drug.
Precautions
CONTRAINDICATIONS:
- None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug may be taken with or without food.
- Tablets should be swallowed whole; not broken, crushed, or chewed.
- If a dose is missed or vomited, do not make up the dose but take the next dose at its scheduled time.
Storage requirements:
- Dispense this drug in the original package with the desiccant cartridge.
- Store at 20C to 25C (68F to 77F), excursions permitted between 15C to 30C (59F to 86F).
- Protect from moisture.
- Discard any unused drug remaining after 6 weeks of first opening the bottle.
Frequently asked questions
More about capmatinib
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.